Skip to main content

Vivo Capital — Portfolio, Page 7

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

165
Companies
$18.1B
Total invested
$138.9M
Avg. check
22
Industries
Biotechnology 17Pharmaceutical 10Health Care 9Medical 7Therapeutics 4Life Science 3+16 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 145165 of 165
Platelet BioGenesis
November 2021

Platelet Biogenesis is an allogeneic cell therapy company that focuses on platelet biology.

Biotechnology · Watertown$75.5M Series B
Neurogastrx
August 2021

A private biopharmaceutical company .

Biotechnology · Woburn$60.0M Series B
Bolt Biotherapeutics
June 2021

Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer immunotherapy.

Biotechnology · Redwood City$15.0M Post Ipo Equity
Telomere Therapeutics
May 2021

Telomere Therapeutics is a University of Barcelona spinoff developing telomerase gene therapy to treat pulmonary fibrosis

Biotechnology · Barcelona$2.3M Seed
Fortis Therapeutics
March 2021

Fortis Therapeutics is an immuno-oncology biotech focused on developing new antibody drug conjugate therapies against CD46.

Biotechnology · La Jolla$40.0M Series A
MiiMOSA
March 2021

MiiMOSA operates a crowd funding platform dedicated to agriculture and food.

Agriculture · Paris$8.9M Series Unknown
Satsuma Pharmaceuticals
March 2021

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product.

Biotechnology · South San Francisco$80.0M Post Ipo Equity
Innocare
February 2021

InnoCare is a Chinese biopharmaceutical company that develops treatment for cancer and autoimmune diseases.

Biotechnology · ChangpingPost Ipo Equity
Design Therapeutics
January 2021

Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders.

Biotechnology · Solana Beach$125.0M Series B
Passage Bio
January 2021

Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.

Biotechnology · Philadelphia$154.0M Post Ipo Equity
Kira Pharmaceuticals
January 2021

Kira Pharmaceuticals is a Biotechnology Research Company.

Biotechnology · Hong Kong$53.5M Series B
Homology Medicines
November 2020

Homology Medicines is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases.

Alternative Medicine · Lexington$60.0M Post Ipo Equity
PatientPop
August 2020

PatientPop is the only complete practice growth solution that empowers healthcare providers to thrive in the digital age.

Digital Marketing · Santa Monica$50.0M Series C
Citrine Medicine
July 2020

Citrine Medicine is a rare disease-focused pharmaceutical firm.

Pharmaceutical · Cambridge$80.0M Series A
Telum Therapeutics
July 2020

Telum Therapeutics is a biotechnology company.

Biotechnology · Pamplona$4.7M Seed
Tranquis Therapeutics
July 2020

Tranquis Therapeutics is focused on the discovery and development of therapies to treat neurodegenerative and aging-related diseases.

Biotechnology · San Mateo$30.0M Series A
ReadCoor
January 2020

Leader in true multi-omic spatial sequencing

Biotechnology · Cambridge$27.0M Series B
Genetron Health
November 2019

Genetron Health is a world-leading expert in precision medicine.

Clinical Trials · Beijing$71.0M Series D
Metacrine
September 2019

Metacrine is a clinical-stage bio pharmaceutical company focused on building an innovative pipeline of best-in-class drugs.

Biotechnology · San Diego$50.0M Debt Financing
Medeor Therapeutics
January 2018

Medeor Therapeutics is a biotechnology company that dedicates to dedicates to the development of personalized cellular immunotherapies.

Biotechnology · South San Francisco$18.8M Grant
Outpost Medicine
November 2017

Outpost Medicine is a biopharmaceutical company

Biopharma · Indianapolis$20.0M Series A

Where Vivo Capital invests

Biotechnology17
Pharmaceutical10
Health Care9
Medical7
Therapeutics4
Life Science3

About Vivo Capital's portfolio

How many companies has Vivo Capital invested in?

Vivo Capital has invested in 165 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Vivo Capital invest in?

Vivo Capital's top investment sectors include Biotechnology, Pharmaceutical, Health Care, Medical, Therapeutics. The firm invests across 22 different industry categories.

What is Vivo Capital's largest investment?

Among tracked funding rounds, Passage Bio received $154.0M in a Post Ipo Equity round. Vivo Capital's total known invested capital is $18.1B.

What is the average investment size for Vivo Capital?

Vivo Capital's average investment size is $138.9M across its portfolio of 165 companies.

What are Vivo Capital's most recent investments?

Recent Vivo Capital portfolio additions include Platelet BioGenesis, Neurogastrx, Bolt Biotherapeutics, Telomere Therapeutics, Fortis Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 165 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →